计算机筛选发现匹莫齐特可克服去势抵抗性前列腺癌卡巴他赛耐药
本研究通过递增卡巴他赛浓度建立DU145CR和PC3CR耐药细胞系,利用Connectivity Map进行计算机药物筛选,发现匹莫齐特可逆转卡巴他赛耐药基因表达特征。体外和异种移植小鼠模型证实匹莫齐特与卡巴他赛联用具有协同抗肿瘤效应,其作用靶点可能为AURKB和KIF20A。
要点
- 匹莫齐特对卡巴他赛耐药细胞DU145CR具有显著抗肿瘤作用。
- 匹莫齐特与卡巴他赛联用在体外和体内均显示协同效应。
- AURKB和KIF20A高表达是前列腺癌不良预后因素,且与卡巴他赛耐药相关。
核心结论
- 匹莫齐特通过靶向AURKB和KIF20A,有望克服去势抵抗性前列腺癌的卡巴他赛耐药。
研究设计与样本
- 研究通过递增卡巴他赛浓度诱导建立DU145CR和PC3CR耐药细胞系,并利用Connectivity Map进行计算机药物筛选。
- 在异种移植小鼠模型中验证药物联用的体内效果。
主要发现
- 匹莫齐特对DU145CR细胞具有显著抗肿瘤效果。
- 匹莫齐特与卡巴他赛联用在DU145CR细胞体外和体内均产生协同效应。
- 微阵列分析确定AURKB和KIF20A为匹莫齐特在卡巴他赛耐药CRPC中的潜在靶点。
- DU145CR细胞的AURKB和KIF20A表达显著高于非卡巴他赛耐药细胞系。
- 抑制AURKB和KIF20A对DU145CR异种移植肿瘤具有抗肿瘤作用。
临床怎么用
- 匹莫齐特联合卡巴他赛可能成为克服CRPC卡巴他赛耐药的治疗策略。
- AURKB和KIF20A高表达或可作为卡巴他赛耐药和不良预后的潜在生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The taxane cabazitaxel (CBZ) is a promising treatment for docetaxel-resistant castration-resistant prostate cancer (CRPC). However, the survival benefit with CBZ for patients with CRPC is limited. This study used screening tests for candidate drugs targeting CBZ-resistant-related gene expression and identified pimozide as a potential candidate for overcoming CBZ resistance in CRPC. METHODS: We established CBZ-resistant cell lines, DU145CR and PC3CR by incubating DU145 cells and PC3 cells with gradually increasing concentrations of CBZ. We performed in silico drug screening for candidate drugs that could reprogram the gene expression signature of a CBZ-resistant prostate cancer cells using a Connectivity Map. The in vivo effect of the drug combination was tested in xenograft mice models. RESULTS: We identified pimozide as a promising candidate drug for CBZ-resistant CRPC. Pimozide had a significant antitumor effect on DU145CR cells. Moreover, combination treatment with pimozide and CBZ had a synergic effect for DU145CR cells in vitro and in vivo. Microarray analysis identified AURKB and KIF20A as potential targets of pimozide in CBZ-resistant CRPC. DU145CR had significantly higher AURKB and KIF20A expression compared with a non-CBZ-resistant cell line. Inhibition of AURKB and KIF20A had an antitumor effect in DU145CR xenograft tumors. Higher expression of AURKB and KIF20A was a poor prognostic factor of TGCA prostate cancer cohort. CBZ-resistant prostate cancer tissues in our institution had higher AURKB and KIF20A expression. CONCLUSIONS: Pimozide appears to be a promising drug to overcome CBZ resistance in CRPC by targeting AURKB and KIF20A.
引用
- Hongo H, Kosaka T, Suzuki Y, et al. Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening. Prostate Cancer Prostatic Dis. 2021. PMID: 34593983. doi:10.1038/s41391-021-00426-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。